ScoreWhy is Akums Drugs & Pharmaceuticals Ltd ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 9.70%
- Poor long term growth as Net Sales has grown by an annual rate of 6.10% and Operating profit at 17.54% over the last 5 years
2
Negative results in Sep 25
- INTEREST(Latest six months) At Rs 46.44 cr has Grown at 380.25%
- PBT LESS OI(Q) At Rs 33.30 cr has Fallen at -49.6% (vs previous 4Q average)
- PAT(Q) At Rs 40.78 cr has Fallen at -50.1% (vs previous 4Q average)
3
Falling Participation by Institutional Investors
- Institutional investors have decreased their stake by -1.54% over the previous quarter and collectively hold 11.55% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
4
Below par performance in long term as well as near term
- Along with generating -31.23% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Akums Drugs for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Akums Drugs
5.47%
-0.85
36.83%
Sensex
-4.3%
0.44
11.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.10%
EBIT Growth (5y)
17.54%
EBIT to Interest (avg)
4.74
Debt to EBITDA (avg)
2.32
Net Debt to Equity (avg)
-0.50
Sales to Capital Employed (avg)
1.78
Tax Ratio
3.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.55%
ROCE (avg)
7.85%
ROE (avg)
9.70%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
24
Industry P/E
31
Price to Book Value
2.50
EV to EBIT
20.35
EV to EBITDA
13.58
EV to Capital Employed
3.98
EV to Sales
1.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
17.63%
ROE (Latest)
9.70%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
NET SALES(Q)
Highest at Rs 1,159.59 cr
PBDIT(Q)
Highest at Rs 146.86 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 12.66%
PBT LESS OI(Q)
Highest at Rs 83.47 cr.
-7What is not working for the Company
INTEREST(Latest six months)
At Rs 47.04 cr has Grown at 69.94%
Loading Valuation Snapshot...
Here's what is working for Akums Drugs
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 83.47 cr has Grown at 49.5% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 55.83 CrMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Net Sales - Quarterly
Highest at Rs 1,159.59 cr
in the last five quartersMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 146.86 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 12.66%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 83.47 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Here's what is not working for Akums Drugs
Interest - Latest six months
At Rs 47.04 cr has Grown at 69.94%
over previous Half yearly periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Non Operating Income - Quarterly
Highest at Rs 34.33 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
